HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Papillomavirus Research

Volumn 2, Issue , 2016, Pages 141-144

  Beachler, Daniel C ^a   Waterboer, Tim ^b   Pierce Campbell, Christine M ^c   Ingles, Donna J ^d   Lang Kuhs, Krystle A ^a   Nyitray, Alan G ^e   Hildesheim, Allan ^a   Pawlita, Michael ^b   Kreimer, Aimée R ^a   Giuliano, Anna R ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anal cancer; HPV; HPV16 E6 seropositivity; Oropharyngeal cancer; Penile cancer

Indexed keywords

PROTEIN E6; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ANAL INFECTION; ANUS DISEASE; ARTICLE; CONTROLLED STUDY; GENITAL TRACT INFECTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE;

EID: 84980317614     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2016.07.003     Document Type: Article

References (17)

1. [1] Tommasino, M., The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol. 26 (2014), 13–21.
2. [2] Lang Kuhs, K.A., Anantharaman, D., Waterboer, T., Johansson, M., Brennan, P., Michel, A., et al. Human Papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: a pooled analysis. Cancer Epidemiol. Biomark. Prev. 24 (2015), 683–689.
3. [3] Bertisch, B., Franceschi, S., Lise, M., Vernazza, P., Keiser, O., Schoni-Affolter, F., et al. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the swiss HIV cohort study. Am. J. Epidemiol. 178 (2013), 877–884.
4. [4] Lang Kuhs, K.A., Pawlita, M., Gibson, S.P., Schmitt, N.C., Trivedi, S., Argiris, A., et al. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol. 42 (2016), 46–52.
5. [5] Kreimer, A.R., Johansson, M., Waterboer, T., Kaaks, R., Chang-Claude, J., Drogen, D., et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 31 (2013), 2708–2715.
6. [6] Kreimer, A.R., Brennan, P., Lang Kuhs, K.A., Waterboer, T., Clifford, G., Franceschi, S., et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J. Clin. Oncol. 33 (2015), 877–884.
7. [7] Giuliano, A.R., Lazcano-Ponce, E., Villa, L.L., Flores, R., Salmeron, J., Lee, J.H., et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol. Biomark. Prev. 17 (2008), 2036–2043.
8. [8] Pierce Campbell, C.M., Kreimer, A.R., Lin, H.Y., Fulp, W., O'Keefe, M.T., Ingles, D.J., et al. Long-term persistence of oral human Papillomavirus Type 16: the HPV Infection in Men (HIM) study. Cancer Prev. Res., 2015.
9. [9] Kreimer, A.R., Campbell, C.M.P., Lin, H., Fulp, W., Papenfuss, M.R., Abrahamsen, M.E.T.A.L., Incidence and clearance of oral human Papillomavirus infection in men: the HIM cohort study. Lancet 382:9895 (2013), 877–887.
10. [10] Nyitray, A.G., Carvalho da Silva, R.J., Baggio, M.L., Lu, B., Smith, D., Abrahamsen, M., et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J. Infect. Dis. 203 (2011), 49–57.
11. [11] Waterboer, T., Sehr, P., Pawlita, M., Suppression of non-specific binding in serological Luminex assays. J. Immunol. Methods 309 (2006), 200–204.
12. [12] Sitas, F., Egger, S., Urban, M.I., Taylor, P.R., Abnet, C.C., Boffetta, P., et al. InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J. Natl. Cancer Inst. 104 (2012), 147–158.
13. [13] Carter, J.J., Koutsky, L.A., Hughes, J.P., Lee, S.K., Kuypers, J., Kiviat, N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181 (2000), 1900011–1900019.
14. [14] Gillison, M.L., Broutian, T., Pickard, R.K., Tong, Z.Y., Xiao, W., Kahle, L., et al. Prevalence of oral HPV Infection in the United States, 2009–2010. JAMA 307 (2012), 693–703.
15. [15] Beachler, D.C., D'Souza, G., Sugar, E.A., Xiao, W., Gillison, M.L., Natural history of anal versus oral HPV infection in HIV-infected men and women. J. Infect. Dis. 208:2 (2013), 330–339.
16. [16] Nyitray, A.G., Chang, M., Villa, L.L., Carvalho da Silva, R.J., Baggio, M.L., Abrahamsen, M., et al. The natural history of genital human papillomavirus among HIV-negative men having sex with men and men having sex with women. J. Infect. Dis. 212 (2015), 202–212.
17. [17] Chaturvedi, A.K., Engels, E.A., Pfeiffer, R.M., Hernandez, B.Y., Xiao, W., Kim, E., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29 (2011), 4294–4301.